3
Participants
Start Date
March 4, 2019
Primary Completion Date
November 6, 2019
Study Completion Date
November 6, 2019
M6620
Participants received 90 milligrams per square meter (mg/m\^2) of M6620, intravenously (IV) on Day 2 of every 3 weeks (Q3W) cycle for a maximum of 6 cycles in combination treatment with carboplatin and avelumab on Day 1. The M6620 dose may be de-escalated to 60 mg/m\^2, or 40 mg/m\^2.
Avelumab
Participants received IV infusion of avelumab 1600 mg on Day 1 of each Q3W cycle for maximum of 6 cycles in combination treatment with carboplatin and M6620. Thereafter, avelumab 800 mg intravenously on Day 1 of every two weeks as a maintenance mono-therapy until progressive disease (PD), unacceptable toxicity, withdrawal of consent, or death.
Carboplatin
Participants received carboplatin area under the concentration-time curve 5 on Day 1 of each Q3W cycle for a maximum of 6 cycles in combination treatment with avelumab and M6620.
Mount Sinai - PRIME, New York
Covenant Health Care, Saginaw
Peggy & Charles Stephenson Oklahoma Cancer Ctr, Oklahoma City
Mary Crowley Cancer Research Centers, Dallas
Marin Cancer Care, Inc., Greenbrae
The Stamford Hospital, Stamford
Memorial Sloan Kettering Cancer Center, New York
UZ Leuven, Leuven
CHU Sart Tilman, Liège
GZA Ziekenhuizen - Campus Sint-Augustinus, Wilrijk
Royal Cornwall Hospital, Truro
Royal Marsden Hospital, Sutton
Royal Marsden Hospital, London
Merck KGaA, Darmstadt, Germany
INDUSTRY
EMD Serono Research & Development Institute, Inc.
INDUSTRY